Overview Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis Status: COMPLETED Trial end date: 2025-03-27 Target enrollment: Participant gender: Summary This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.Phase: PHASE2 Details Lead Sponsor: Aclaris Therapeutics, Inc.